Rhythm Pharmaceuticals 将来の成長

Future 基準チェック /56

Rhythm Pharmaceuticals利益と収益がそれぞれ年間71.4%と45.7%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-35.7% 71%なると予測されています。

主要情報

71.4%

収益成長率

71.01%

EPS成長率

Biotechs 収益成長	23.8%
収益成長率	45.7%
将来の株主資本利益率	-35.74%
アナリストカバレッジ	Good
最終更新日	22 Dec 2025

今後の成長に関する最新情報

The Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Nov 07

Recent updates

Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster

Dec 11

The Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Nov 07

Revenues Not Telling The Story For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) After Shares Rise 33%

Jul 10

Rhythm Pharmaceuticals (NASDAQ:RYTM) Has Debt But No Earnings; Should You Worry?

Jun 25

Label Expansion And Global Healthcare Will Widen Future Market Opportunities

May 26 Label expansion and global commercialization of IMCIVREE are set to drive substantial revenue growth and broaden market reach.

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares Climb 36% But Its Business Is Yet to Catch Up

May 04

Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)

Jun 12

Rhythm Pharmaceuticals: Action Too Specific

Feb 23

業績と収益の成長予測

NasdaqGM:RYTM - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2027	539	47	-29	61	10
12/31/2026	293	-174	-176	-112	15
12/31/2025	188	-205	-198	-148	15
9/30/2025	174	-198	-149	-109	N/A
6/30/2025	156	-188	-108	-108	N/A
3/31/2025	137	-174	-114	-113	N/A
12/31/2024	130	-265	-154	-114	N/A
9/30/2024	113	-262	-165	-124	N/A
6/30/2024	102	-261	-169	-128	N/A
3/31/2024	92	-274	-182	-140	N/A
12/31/2023	77	-185	-142	-136	N/A
9/30/2023	62	-186	-146	-141	N/A
6/30/2023	44	-182	-164	-159	N/A
3/31/2023	34	-181	-161	-156	N/A
12/31/2022	24	-181	-174	-173	N/A
9/30/2022	17	-181	-173	-180	N/A
6/30/2022	13	-176	-166	-173	N/A
3/31/2022	5	-166	-160	-166	N/A
12/31/2021	3	-70	-139	-146	N/A
9/30/2021	1	-62	-135	-135	N/A
6/30/2021	0	-60	-122	-122	N/A
3/31/2021	0	-56	-120	-119	N/A
12/31/2020	N/A	-134	-122	-122	N/A
9/30/2020	N/A	-132	-125	-125	N/A
6/30/2020	N/A	-134	-132	-132	N/A
3/31/2020	N/A	-146	-130	-127	N/A
12/31/2019	N/A	-141	-126	-123	N/A
9/30/2019	N/A	-133	-115	-112	N/A
6/30/2019	N/A	-115	N/A	-95	N/A
3/31/2019	N/A	-87	N/A	-82	N/A
12/31/2018	N/A	-74	N/A	-62	N/A
9/30/2018	N/A	-59	N/A	-49	N/A
6/30/2018	N/A	-53	N/A	-40	N/A
3/31/2018	N/A	-47	N/A	-34	N/A
12/31/2017	N/A	-38	N/A	-29	N/A
9/30/2017	N/A	-36	N/A	-28	N/A
6/30/2017	N/A	-32	N/A	-24	N/A
3/31/2017	N/A	-30	N/A	-24	N/A
12/31/2016	N/A	-29	N/A	-23	N/A
9/30/2016	N/A	-27	N/A	-21	N/A
6/30/2016	N/A	-23	N/A	-18	N/A
3/31/2016	N/A	-17	N/A	-13	N/A
12/31/2015	N/A	-12	N/A	-7	N/A
9/30/2015	N/A	-6	N/A	-4	N/A
6/30/2015	N/A	-3	N/A	-4	N/A
3/31/2015	N/A	-5	N/A	-6	N/A

アナリストによる今後の成長予測

収入対貯蓄率: RYTMは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 3.3% ) よりも高い成長率であると考えられます。

収益対市場: RYTM今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: RYTM今後 3 年以内に収益を上げることが予想されます。

収益対市場: RYTMの収益 ( 45.7% ) US市場 ( 10.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: RYTMの収益 ( 45.7% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: RYTM 3 年以内に赤字になると予測されています。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/12/28 18:17
終値	2025/12/26 00:00
収益	2025/09/30
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Rhythm Pharmaceuticals, Inc. 15 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。24

アナリスト	機関
Tazeen Ahmad	BofA Global Research
Whitney Ijem	Canaccord Genuity
Samantha Lynn Semenkow	Citigroup Inc

Rhythm Pharmaceuticals 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

The Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Consensus EPS estimates fall by 14%, revenue upgraded

Consensus EPS estimates fall by 61%

Price target increased by 9.0% to US$53.78

Price target increased by 10% to US$52.67

Forecast to breakeven in 2026

Recent updates

Rhythm Pharmaceuticals, Inc. Announces Resignation of Camille L. Bedrosian from Board of Directors, Effective December 16, 2025

Rhythm Pharmaceuticals, Inc. to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster

The Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Rhythm Pharmaceuticals, Inc. Announces FDA Extension of Review Period for IMCIVREE®? (setmelanotide) for Patients with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc. to Report Q3, 2025 Results on Nov 04, 2025

Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 05, 2025

Rhythm Pharmaceuticals, Inc. Presents Data on Mc4r Agonists Setmelanotide and Bivamelagon At Endo 2025

Rhythm Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $175.00004 million.

Revenues Not Telling The Story For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) After Shares Rise 33%

Rhythm Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Rhythm Pharmaceuticals, Inc. Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-Controlled Phase 2 Trial in Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc. Announces Three Late-Breaking Data Abstracts Accepted for Presentation At Endocrine Society

Rhythm Pharmaceuticals (NASDAQ:RYTM) Has Debt But No Earnings; Should You Worry?

Label Expansion And Global Healthcare Will Widen Future Market Opportunities

Rhythm Pharmaceuticals, Inc. Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for Up to Nine Months in French Early-access Program

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares Climb 36% But Its Business Is Yet to Catch Up

Rhythm Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 07, 2025

Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder

Rhythm Pharmaceuticals Announces Pivotal Phase 3 Transcend Trial Meets Primary Endpoint with -19.8%

Rhythm Pharmaceuticals, Inc., Annual General Meeting, Jun 24, 2025

Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven

Rhythm Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 26, 2025

Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (Setmelanotide) for Patients as Young as 2 Years Old

Rhythm Pharmaceuticals: A Key Year Ahead

Rhythm Pharmaceuticals Announces IMCIVREE (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, Including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in the Lancet Diabetes & Endocrinology

Rhythm Pharmaceuticals Announces Five New Data Presentations At Obesityweek 2024

Rhythm Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024

Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck

Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for Imcivree® (Setmelanotide) in Patients as Young as 2 Years Old

Rhythm Pharmaceuticals, Inc. Announces European Commission Expands IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

Rhythm Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Rhythm Pharmaceuticals, Inc. Announces Appointment of Alastair Garfield, as Chief Scientific Officer

Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Index

Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients Between 2 and 6 Years Old with Bardet Biedl Syndrome

Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)

New minor risk - Profitability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Rhythm Pharmaceuticals, Inc. Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology

Rhythm Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024

Rhythm Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

Executive VP & Head of North America notifies of intention to sell stock

Perceptive Advisors Engages in Discussion with Rhythm Pharmaceuticals

Consensus EPS estimates fall by 14%, revenue upgraded

Consensus EPS estimates fall by 61%

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Rhythm Pharmaceuticals: Action Too Specific

Rhythm Pharmaceuticals, Inc. Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

Chief Technical Officer notifies of intention to sell stock

New minor risk - Profitability

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Price target increased by 9.0% to US$53.78

Price target increased by 10% to US$52.67

Forecast to breakeven in 2026

Chief Technical Officer notifies of intention to sell stock

Price target increased by 7.8% to US$47.67

CFO & Treasurer exercised options and sold US$860k worth of stock

Price target increased by 8.4% to US$44.22

CFO & Treasurer notifies of intention to sell stock

Chief Technical Officer notifies of intention to sell stock